HISTOPATHOLOGICAL DIAGNOSIS CRITERIA IN ENDOMETRIAL HYPERPLASIA

  • Alexandra PANGAL “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irina NEGRU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C. PRICOP “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Elena MIHALCEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • G. COSTACHESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • D. NEGRU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Endometrial hyperplasia is a condition of the abnormal proliferative lesions of the endometrium. Aim: To highlight the value of histopathological examinations with assessment of the ways to obtain endometrial biopsies and the appreciation of the contribution of different histopathological techniques that can be used to establish a correct and complete diagnosis. Material and methods: The study was conducted in a group of 50 patients diagnosed with endometrial hyperplasia. In all cases the bioptic curettage was performed using a curette to obtain more abundant material for the histopathological examination. Results: Histopathological diagnosis guides the therapeutic attitude and has an important prognostic value. The study group was characterized by histoarchitectonic heterogeneity, presented even in the same case. Histoarchitectonic and cytological changes differentiate endometrial hyperplasia from physiological proliferative endometrium. Conclusions: The diagnosis of certainty between the four types of endometrial proliferation established by the WHO can only be done through the histopathological examination.

Author Biographies

Alexandra PANGAL, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Mother and Child Medicine

Irina NEGRU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Surgery (II)

C. PRICOP, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Surgery (II)

Elena MIHALCEANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Mother and Child Medicine

G. COSTACHESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Mother and Child Medicine

D. NEGRU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Surgery (II)

References

1. Poiană C, Mușat M, Carsote M, Chirițã C. Premenstrual dysphoric disorder: neuroendocrine interfer-ences. Rev. Med. Chir. Soc. Med. Nat. Iasi 2009; 113(4): 996-1000.
2. Simionescu C, Florescu M, Niculescu M, Bălă S, Manea M. Histopathologic aspects of the limited endometrial hyperplasias-a study concerning 149 cases. Romanian Journal of Morphology and Em-bryology 2005; 46(1): 51-55.
3. Yilmaz I, Baloglu H, Haholu A, Berber U, Yildirim S, Ergur AR. Objective risk definition for endo-metrial lesion spectrum: a diagnostic algorithm. Gynecol Oncol 2007; 105(2): 451-456.
4. Mazur MT. Endometrial hyperplasia/adenocarcinoma. a conventional approach. Ann Diagn Pathol. 2005; 9(3):174-181.
5. Sezgin M, Ismail AA., Histopathological challenges in the diagnosis of endometrial hyperplasia and carcinoma. Diagnostic Histopathology 2006; 12(5): 312-324.
6. Hammond R, Johnson J. Endometrial hyperplasia. Current Obstetrics & Gynaecology 2001; 11(3): 160-163.
7. Stolnicu S, Rădulescu D, Mocan S, Pantazescu A, Coroş M., The significance of morphologic and immunohistochemical patterns in the diagnosis of undifferentiated endometrial sarcoma. Rev Med Chir.2004; 108(4): 791-796.
8. Kojo R, Rawish MD, Mohamed M, Desouki MD, Oluwole Fadare MD. Atypical mucinous glandular proliferations in endometrial samplings: follow-up and other clinicopathological findings in 41 cases. Human Pathology 2017; 63: 53-62.
9. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985; 56(2): 403-412.
10. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selec-tive estrogen receptor modulator with improved selectivity. Endocrinology 2005; 146(9): 3999-4008.
11. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL. Management of endometrial precancers. Obstet. Gynecol 2012; 120: 1160-1175.
12. Tanner E, Puechl A, Levinson K, Havrilesky LJ, Sinno A, Secord AA, Fader AN, Lee PS. Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. Gynecol. Oncol 2017; 147 (3): 535-540.
13. Gafton B, Porumb V, Ungurianu S, Marinca MV, Cocea C, Croitoru A, et al. Hepatocellular carcino-ma: insight in the biological treatment beyond sorafenib. Journal of BUON 2014; 19(4): 858-866.
14. Papadia A, Gasparri ML, Siegenthaler F, Imboden S, Mohr S, Mueller MD. FIGO stage IIIC endome-trial cancer identification among patients with complex atypical hyperplasia, grade 1 and 2 endometrioid endometrial cancer: laparoscopic indocy- anine green sentinel lymph node mapping versus frozen section of the uterus, why get around the problem? J. Cancer Res. Clin. Oncol. 2017;143 (3): 491-497.
15. Cobzeanu, MD, Costinescu, V, Rusu, CD, Mihailovici, S, Grigoras, M, Miron, L, Paduraru, D, Ara-ma, A. Laryngotracheal nonhodgkin's lymphoma. Chirurgia 2010; 105(1): 131-136.
Published
2018-04-04